Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-month, International, Parallel Group, Randomised, Multi-centre, Double-blind, Placebo-controlled Trial to Examine the Effect of Actovegin® Treatment Given First Intravenously and Subsequently Orally Over 6 Months, in Subjects With Post-stroke Cognitive Impairment (PSCI).

NCT01582854 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01582854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01582854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-month, International, Parallel Group, Randomised, Multi-centre, Double-blind, Placebo-controlled Trial to Examine the Effect of Actovegin® Treatment Given First Intravenously and Subsequently Orally Over 6 Months, in Subjects With Post-stroke Cognitive Impairment (PSCI).
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
November 30, 2014
Enrollment
503 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

post-stroke cognitive impairment (psci)